SCHEMBL1473772

SCHEMBL1473772

O=C(NCc1ccccn1)Nc1cc(-c2ccco2)on1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.55
ALOX15 P16050 2/20 0.55
RAB9A P51151 3/20 0.54
NPC1 O15118 2/20 0.54
ALDH1A1 P00352 3/20 0.54
KMT2A Q03164 7/20 0.53
MEN1 O00255 2/20 0.53
ADORA2A P29274 2/20 0.53
ADORA1 P30542 2/20 0.53
MAPT P10636 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
KDM4E B2RXH2 1/20 0.53
POLB P06746 1/20 0.53
THRB P10828 1/20 0.53
PKM P14618 1/20 0.53
HPGD P15428 1/20 0.53
NR4A1 P22736 1/20 0.53
APEX1 P27695 1/20 0.53
CASP1 P29466 1/20 0.53
PTPN7 P35236 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1475683 0.84 RAB9A (0.70) SMN1; SMN2ALOX15RAB9ANPC1KMT2A
SCHEMBL1474978 0.84 ALDH1A1 (0.70) SMN1; SMN2RAB9ANPC1ALDH1A1KMT2A
SCHEMBL1475078 0.83 NPC1 (0.72) SMN1; SMN2ALOX15RAB9ANPC1ALDH1A1
SCHEMBL1474264 0.83 ALDH1A1 (0.47) SMN1; SMN2ALOX15RAB9ANPC1ALDH1A1
SCHEMBL1474947 0.82 ALDH1A1 (0.57) SMN1; SMN2ALOX15RAB9ANPC1ALDH1A1
SCHEMBL1474912 0.81 SMN1; SMN2 (0.54) SMN1; SMN2ALOX15RAB9ANPC1KMT2A
SCHEMBL1475156 0.80 KMT2A (0.72) SMN1; SMN2ALOX15RAB9ANPC1ALDH1A1
SCHEMBL15190165 0.80 ALDH1A1 (0.52) SMN1; SMN2ALOX15RAB9ANPC1ALDH1A1
SCHEMBL1475137 0.77 HPGD (0.53) SMN1; SMN2ALOX15RAB9ANPC1ALDH1A1
SCHEMBL1178252 0.76 RAB9A (0.71) SMN1; SMN2RAB9ANPC1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 SMN1; SMN2 3980/4885ALOX15 1670/4885RAB9A 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.